From: @sanidad.gob.es
To: EU NITAG COLLABORATION

Subject: RE: FOR contribution - in preparation of NITAG webinar on booster doses - 20 August 2021

Date: 18 August 2021 19:58:26

Attachments: <u>image001.gif</u>

image002.png image003.png image004.png

image005.png NITAGs Webinar questions120821 ES.xlsx

EXTERNAL EMAIL!

Do not click on any links, open attachments or reply, unless you recognise the sender's email address (@sanidad.gob.es)

Dear colleagues,

Please find a summary of the situation in Spain (in red) instead of the previous text.


Kind regards,

Secretariat Spain's NITAG MoH Spain

Teléfono: (+34)

E-mail: @sanidad.gob.es

ATENCIÓN: cambio de dirección email



Asunto: FOR contribution - in preparation of NITAG webinar on booster doses - 20 August 2021

Dear EU/EEA NITAG Members -

In preparation for the NITAG webinar on 20 August 2021 at 14H30, kindly asking for your support in the following:

- 1. Would you please review the information contained in the Excel file for your respective country and make any amendments you feel necessary. The information originates from previous requests we made to you as well as from information collected on a regular basis by the EC through the ISAA questionnaire. Please kindly get back to us by 18 August end of day replying to this email if you can so that we can summarise the info for the webinar on Friday. Thank you so much
- 2. Would you please consider the question raised by colleagues in Portugal and copied below. This will be brought for discussion at the NITAG meeting on Friday and your input/thoughts would be much appreciated. Not an easy question and limited evidence available to date but grateful for contributing to the discussion on Friday.

Dear colleagues,

The Portuguese NITAG would like your opinion regarding the usefulness of serologic assays to evaluate a putative reduction of vaccine effectiveness.

We did not find evidence that would provide compelling support for the use of serologic data as a surrogate for vaccine effectiveness regarding the potential need for an immunization boost. We are considering, however, that serologic assays can be informative in very specific situations, namely to evaluate the vaccine response in people under significant immune suppression.

We are favoring the monitoring of vaccine effectiveness in different population groups (namely the elderly), rather than using serologic information, to inform decisions regarding the most adequate time for a boost.

However, we would like to have the input from the other NITAGs, as we believe that in a technical issue such as the use of serology information, it would be desirable if we could have a consistent policy between countries

Thank you in advance for your support.

Best regards,
The Portuguese NITAG

Thank you in advance for your support and looking forward to discussions on Friday

Kind regards





European Centre for Disease Prevention and Control (ECDC) Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone +46 (0)8 58 60 10 00 / Fax +46 (0)8 58 60 10 01

www.ecdc.europa.eu



Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.

CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo indique, no comunique su contenido a terceros y proceda a su destrucción.

CONFIDENTIALITY. The content of this message and any attached information is confidential and exclusively for the use of the addresser. If you are not the addresser, we ask you to notify to the sender, do not pass its content and delete the original.